|
1）Rouvier E, Luciani MF, Mattei MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993; 150: 5445-56
|
|
|
|
2）Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995; 3: 811-21
|
|
|
|
|
3）Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002; 71: 1-8
|
|
|
|
|
|
4）Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004; 21: 467- 76
|
|
|
|
|
|
5）Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007; 25: 821-52
|
|
|
|
|
|
6）Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7: 145-73
|
|
|
|
|
|
7）Infante-Duarte C, Horton HF, Byrne MC, et al. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 2000; 165: 6107-15
|
|
|
|
|
|
8）Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002; 17: 375-87
|
|
|
|
|
|
9）Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003; 171: 6173-7
|
|
|
|
|
|
10）Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003; 278: 1910-4
|
|
|
|
|
|
11）Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007; 25: 221-42
|
|
|
|
|
|
12）Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4＋ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6: 1123-32
|
|
|
|
|
|
13）Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6: 1133-41
|
|
|
|
|
|
14）Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201: 233-40
|
|
|
|
|
|
15）Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003; 198: 1951-7
|
|
|
|
|
|
16）Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-8
|
|
|
|
|
|
17）Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the TH17 lineage. Nature. 2006; 441: 231-34
|
|
|
|
|
|
18）Ivanov, II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17＋ T helper cells. Cell. 2006; 126: 1121-33
|
|
|
|
|
|
19）Zhou L, Ivanov, II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8: 967-74
|
|
|
|
|
|
20）Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006; 7: 929-36
|
|
|
|
|
|
21）Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006; 7: 937-45
|
|
|
|
|
|
22）Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006; 177: 566-73
|
|
|
|
|
|
23）Schnyder-Candrian S, Togbe D, Couillin I, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med. 2006; 203: 2715-25
|
|
|
|
|
|
24）Veldhoen M, Hocking RJ, Flavell RA, et al. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol. 2006; 7: 1151-6
|
|
|
|
|
|
25）Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007; 26: 371-81
|
|
|
|
|
|
26）Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007; 448: 484-7
|
|
|
|
|
|
27）Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA. 2007; 104: 12099-104
|
|
|
|
|
|
28）Kryczek I, Wei S, Vatan L, et al. Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17＋ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. J Immunol. 2007; 179: 1423-6
|
|
|
|
|
|
29）Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007; 8: 942-9
|
|
|
|
|
|
30）Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007; 8: 950-7
|
|
|
|
|
|
31）Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007; 8: 639-46
|
|
|
|
|
|
32）Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14: 155-74
|
|
|
|
|
|
33）Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol. 2006; 177: 36-9
|
|
|
|
|
|
34）Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem. 2006; 281: 35603-7
|
|
|
|
|
|
35）Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007; 8: 247-56
|
|
|
|
|
|
36）Iwakura Y. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. 2002; 13: 341-55
|
|
|
|
|
|
37）Nakae S, Saijo S, Horai R, et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA. 2003; 100: 5986-90
|
|
|
|
|
|
38）Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med. 2005; 202: 761-9
|
|
|
|
|
|
39）Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001; 194: 519-27
|
|
|
|
|
|
40）Chackerian AA, Chen SJ, Brodie SJ, et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun. 2006; 74: 6092-9
|
|
|
|
|
|
41）Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006; 176: 1098-106
|
|
|
|
|
|
42）Lieberman LA, Cardillo F, Owyang AM, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004; 173: 1887-93
|
|
|
|
|
|
43）Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis. 2006; 19: 245-52
|
|
|
|
|